Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Deffered Revenue (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 24.42% year-over-year to $28.7 million, compared with a TTM value of $28.7 million through Dec 2025, down 24.42%, and an annual FY2025 reading of $28.7 million, down 24.42% over the prior year.
  • Non-Current Deffered Revenue was $28.7 million for Q4 2025 at Avidity Biosciences, down from $32.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $43.4 million in Q1 2025 and bottomed at $1.2 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $22.9 million, with a median of $28.7 million recorded in 2025.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 81.09% in 2022, then skyrocketed 3211.58% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $6.5 million in 2021, then crashed by 81.09% to $1.2 million in 2022, then surged by 3211.58% to $40.9 million in 2023, then fell by 7.18% to $38.0 million in 2024, then fell by 24.42% to $28.7 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for RNA at $28.7 million in Q4 2025, $32.1 million in Q3 2025, and $40.0 million in Q2 2025.